Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.Int Urogynecol J. 2010; 21 (2009/11/26): 5-26https://doi.org/10.1007/s00192-009-0976-9
- Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review.Neurourol Urodyn. 2013; 32 (2012/08/22): 206-214https://doi.org/10.1002/nau.22296
- Prevalence and burden of overactive bladder in the United States.World J Urol. 2003; 20 (2003/06/18): 327-336https://doi.org/10.1007/s00345-002-0301-4
- Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU guideline amendment 2019.J Urol. 2019; 202 (2019/05/01): 558-563https://doi.org/10.1097/ju.0000000000000309
- Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.Int Urogynecol J. 2014; 25 (2013/11/08): 485-492https://doi.org/10.1007/s00192-013-2250-4
- Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study.J Urol. 2001; 165 (2001/03/21): 1193-1198
- Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.J Urol. 2010; 183 (2010/02/23): 1438-1443https://doi.org/10.1016/j.juro.2009.12.036
- Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.J Urol. 2013; 189 (2012/12/12): 2194-2201https://doi.org/10.1016/j.juro.2012.11.175
- Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine; results from the overactive bladder innovative therapy trial.J Urol. 2009; 182 (2009/07/21): 1055-1061https://doi.org/10.1016/j.juro.2009.05.045
- Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study.Neurourol Urodyn. 2013; 32 (2012/06/08): 24-29https://doi.org/10.1002/nau.22266
- Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders.Int Urogynecol J. 2013; 24 (2012/09/08): 795-799https://doi.org/10.1007/s00192-012-1936-3
- Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients.Neurourol Urodyn. 2020; 39 (2019/12/18): 702-706https://doi.org/10.1002/nau.24254
- Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder.BJU Int. 2019; 123 (2018/12/16): E20-e28https://doi.org/10.1111/bju.14651
- Factors associated with overactive bladder symptom improvement after 1 year of monthly percutaneous tibial nerve stimulation therapy.Neurourol Urodyn. 2019; 38 (2019/05/21): 1676-1684https://doi.org/10.1002/nau.24038
- An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.Neurourol Urodyn. 2015; 34 (2015/03/19): 255-263https://doi.org/10.1002/nau.22559
- Validation of two global impression questionnaires for incontinence.Am J Obstet Gynecol. 2003; 189 (2003/07/16): 98-101https://doi.org/10.1067/mob.2003.379
- Determining the importance of change in the overactive bladder questionnaire.J Urol. 2006; 176: 627-632
- Percutaneous tibial nerve stimulation in the office setting: real-world experience of over 100 patients.Urology. 2018; 113 (2017/12/03): 34-39https://doi.org/10.1016/j.urology.2017.11.026
- Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence.Int Urogynecol J. 2020; (2020/06/24)https://doi.org/10.1007/s00192-020-04325-1
- OnabotulinumtoxinA vs Sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial.JAMA. 2016; 316 (2016/10/05): 1366-1374https://doi.org/10.1001/jama.2016.14617
- Validation of the patient global impression of improvement (PGI-I) for urogenital prolapse.Int Urogynecol J. 2010; 21 (2009/12/17): 523-528https://doi.org/10.1007/s00192-009-1069-5
- Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study.BJOG. 2013; 120 (2012/11/30): 212-216https://doi.org/10.1111/1471-0528.12069
- 8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder.Int Urogynecol J. 2020; 31 (2020/01/14): 905-914https://doi.org/10.1007/s00192-019-04191-6
- Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder.Int Urogynecol J. 2019; 30 (2018/11/24): 1253-1259https://doi.org/10.1007/s00192-018-3822-0
- Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome.Int Urogynecol J. 2018; (2018/12/01)https://doi.org/10.1007/s00192-018-3834-9
- Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder.J Urol. 2010; 183 (2009/11/17): 234-240https://doi.org/10.1016/j.juro.2009.08.160
- A prospective study to evaluate efficacy using the nuro percutaneous tibial neuromodulation system in drug-naive patients with overactive bladder syndrome.Urology. 2019; 131 (2019/06/15): 77-82https://doi.org/10.1016/j.urology.2019.06.002
Declarations of Interest: None.
Financial Disclosure: The authors declare that they have no relevant financial interests.
Disclosures: Dr. Benjamin M. Brucker is an advisor for Urovant, Watkins-Conti, Allergan, Click therapeutics. He is an investigator for Boston Scientific and Allergan. Dr. Victor W. Nitti is an investigator for Medtronic, Allergan, and Astellas. Dr. Kimberly L. Ferrante is an investigator for Valencia Technologies. Dr. Dominique Malacarne Pape is an investigator for Watkins-Conti.